{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '7.1', 'INCLUSION CRITERIA', '1. Age 21 years', '2. Able to understand the informed consent form and provide written informed consent and', 'able to complete outcome measures', '3.', 'Chronic knee pain for longer than 6 months that interferes with functional activities (for', 'example, ambulation, prolonged standing, etc.)', '4. Continued pain in the target knee despite at least 3 months of conservative treatments,', 'including activity modification, home exercise, protective weight bearing, and/or', 'analgesics (for example, acetaminophen or non-steroidal anti-inflammatory drugs', '[NSAIDs])', '5.', 'Positive response (defined as a decrease in numeric pain scores of at least 50%) to a', 'single genicular nerve block of the index knee', '6. Pain on NRS 6 on an 11-point scale for the index knee', '7. Radiologic confirmation of arthritis (x-ray/MRI/CT) of OA grade of 2 (mild), 3 (moderate)', 'or 4 (severe) noted within 6 months for the index knee', '8. An intra-articular hyaluronic acid injection is indicated as an appropriate treatment option', '9. WOMAC Knee Score group at baseline of Score of > 2 (0 to 4 scale) on WOMAC', 'question 1 (Pain) and a mean score of > 1.5 on all five questions of the WOMAC pain', 'subscale.', '10. Analgesics including membrane stabilizers such as Neurontin/gabapentin and', 'antidepressants for pain such as Cymbalta/duloxetine must be clinically stable (defined', 'as stable dosage for 6 weeks prior to the screening visit) and shall not change during', 'the course of the study without approval of the investigator', '11. Agree to see one physician (study physician) for knee pain during the study period', '12. Willing to utilize double barrier contraceptive method if of child bearing potential.', '13. Willing to delay any surgical intervention for the index knee for the period of the study', 'follow up', '14. Willingness to provide informed consent and to comply with the requirements of this', 'protocol for the full duration of the study', '7.2', 'EXCLUSION CRITERIA', '1.', 'Evidence of inflammatory arthritis (for example, rheumatoid arthritis) or other systemic', 'inflammatory condition (for example, gout, fibromyalgia) that could cause knee pain', '2. Evidence of neuropathic pain affecting the index knee', '3. Previous or pending lower limb amputation', '4. Intra-articular steroid injection into the index knee within 90 days from randomization', 'Version #: 4.0', 'Page 23 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '5. Hyaluronic acid injection, platelet rich plasma (PRP), stem cell, or arthroscopic', 'debridement/lavage injection into the index knee within 180 days from randomization', '6. Prior radiofrequency ablation of the genicular nerves of the index knee', '7. Prior partial, resurfacing, or total knee arthroplasty of the index knee (residual hardware)', '8. Clinically significant ligamentous laxity of the index knee', '9.', 'Clinically significant valgus/varus deformities or evidence of pathology (other than', 'osteoarthritis of knee) that materially affects gait or function of the knee or is the', 'underlying cause of the knee pain and/or functional limitations', '10. Body mass index (BMI) > 40 kg/m\u00b2', '11. Extremely thin patients and those with minimal subcutaneous tissue thickness that would', 'not accommodate a radiofrequency lesion of up to 14 mm in diameter to limit the risk of', 'skin burns', '12. Pending or active compensation claim, litigation or disability remuneration (secondary', 'gain)', '13. Pregnant, nursing or intent on becoming pregnant during the study period', '14. Chronic pain associated with significant psychosocial dysfunction', \"15. Beck's Depression Index score of > 22 (indicates clinically depressed state)\", '16. Allergies to any of the medications to be used during the procedures, including known', 'hypersensitivity (allergy) to hyaluronate preparations or allergies to avian or avian-derived', 'products (including eggs, feathers, or poultry)', '17. Active joint infection or systemic or localized infection at needle entry sites (subject may', 'be considered for inclusion once infection is resolved)', '18. History of uncontrolled coagulopathy, ongoing coagulation treatment that cannot be', 'safely interrupted for procedure, or unexplained or uncontrollable bleeding that is', 'uncorrectable.', '19. Identifiable anatomical variability that would materially alter the procedure as described in', 'the protocol', '20. Within the preceding 2 years, subject has suffered from active narcotic addiction,', 'substance, or alcohol abuse', '21. Current prescribed opioid medications greater than 60 morphine equivalent daily opioid', 'dose', '22. Uncontrolled immunosuppression (e.g. AIDS, cancer, diabetes, etc.)', '23. Subject currently implanted with pacemaker, stimulator or defibrillator.', '24. Participating in another clinical trial/investigation within 30 days prior to signing informed', 'consent', '25. Subject unwilling or unable to comply with follow up schedule or protocol requirements', 'Version #: 4.0', 'Page 24 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}